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Mycobacterium tuberculosis was first discovered by Robert Koch in 1882 
and is a human infectious strain that causes lung disease through the 
respiratory tract. M. tuberculosis differs from ordinary bacteria in that it has 
thick membranes on the cell surface and does not stain Gram stain. 
However, when stained with Ziehl-Neelsen, it is difficult to decolorize by 
acid, alcohol and boiling, and this property is called acid-fast. Gram staining 
is negative, but they do not have external membranes and are classified as 
acid-fast gram-positive bacteria. Treatment of patients infected with M. 
tuberculosis is mainly medication. Isoniazid, rifampin, and pyrazinamide are 
used, and streptomycin is also used. 
 Mycobacterium tuberculosis has the largest number of Toxin-Antitoxin 
system pairs among bacteria. The Toxin-Antitoxin system is classified into 
six types according to antitoxin properties. The target protein Rv0660c of 
this study is MazE, an antitoxin of MazEF system, which is one of Type2 
Toxin-Antitoxin system.
 
The Toxin-Antitoxin system plays a role in inhibiting the growth of bacteria 
or leading to death by external stimuli-activated toxins. Antitoxin normally 
binds to toxin and inhibits the activity of toxin. but it breaks down in 
extreme situations. Thus, dissociated toxin induces growth inhibition and 
death. This also induces latency and lowers susceptibility to antibiotics.
We overexpress the N1-44 construct of Rv0660c to characterize the tertiary 
structure of this Rv0660c protein. His-tagged Rv0660c protein was purified 
using Immobilized Metal Affinity Chromatography (IMAC), and the His-tag 
was removed through thrombin cutting to further increase the protein purity. 
As a result, the crystal could be made and the structure could be obtained 
with a high resolution of 1.69 Å.
 The DNA binding experiments of Rv0660c were carried out by NMR and 
EMSA. Rv0660c was labeled with 13C and 15N isotopes. Heteronuclear 
multidimensional NMR spectra were measured and backbone assignments 
were made through HNCO, HNCA, HNCACO, HNCOCA, HNCOCACB and 
HNCACB spectra. The TALOS program was used to predict the secondary 
structure and identify the parts which interact DNA through DNA titration. 
We confirmed the binding of Rv0660c with DNA in vitro from 
Electrophoretic Mobility Shift Assay (EMSA).
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Ⅰ. Introduction
 
1.1 Structure Based Drug Design (SBDD)
SBDD is the way to develop new drugs. In general, designing drug 
molecules while looking at the stereo structure of the target protein is called 
structure-based drug design. To do this, we analyze the 3D structure through 
X-ray crystal structure analysis or NMR. 
 SBDD is far superior in cost and time to traditional drug development 
methods that improve the compounds discovered accidentally from natural 
products such as herbal medicines. The traditional method depends on the 
intuition and experience of the researchers and requires a lot of time and 
effort. It takes 3-5 years to lead discovery. However, if the 
three-dimensional structure of the disease target protein is identified, you can 
shorten up to 2-3 years and save a lot of money. 
In addition, since SBDD is a method of designing drugs in a rational 
manner, it is possible to develop a drug having a high activity and low side 
effect. Since it is a method to develop a drug structurally most suitable for 
a target corresponding to a therapeutic purpose considering an adverse effect 
from the beginning, the probability of entering and passing the clinical trial 
phase is high and the probability of unexpected side effects occurring in 
post marketing can be very low. 
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1.2 Characteristics of Mycobacterium tuberculosis
Tuberculosis has been a terrible infectious disease that has suffered a great 
deal of life around the world, long since it has given much suffering to 
humankind and has been called 'white pest' in the 19th century.
However, now that tuberculosis is in a country with poor sanitation as well 
as malnutrition, tuberculosis is considered a 'forgotten disease' or a 'past 
disease'. However, tuberculosis is a disease that is never forgotten and is 
still a disease that is threatening the health of the world.
It was discovered by Robert Koch in 1882 as a major cause of 
tuberculosis. It grows much slower than other bacteria and can survive long 
in dry conditions due to the fat-rich cell walls. Tuberculosis is most often 
caused by airborne infection (droplet infection). [Issar Smith., 2003]
It is resistant to strong acids and alkalis, but it is vulnerable to heat and 
sunlight. If exposed to direct sunlight, it will die in a few minutes. It is a 
thin and long bacterium, and both ends are dull, round, straight or slightly 
curved. It does not form sporophytes, the cavernous membranes, and has no 
motility. [Issar Smith., 2003]
1.3 Epidemiology of Mycobacterium tuberculosis
According to World Health Organization (WHO), around 5000 patients die 
every day from tuberculosis. It is estimated that the number of new 
tuberculosis cases per year is about 10 million, and the death toll is about 
1.8 million.
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According to the World Health Organization (WHO), the number of TB 
patients in Republic of Korea by 2015 is about 40,000, which is about 80 
per 100,000 people. It is the lowest among OECD member countries. The 
rate of tuberculosis incidence and mortality rate is the number one, and the 
incidence of multi-drug-resistant tuberculosis, which is particularly 
problematic, is also the number one.
It is the immune TB that aggravates the global TB crisis. If you are 
resistant to the first drug known to be the most effective (rifampicin, 
isoniazid), it is judged to be multi-drug-resistant tuberculosis (MDR-TB). In 
addition, when resistant to secondary drugs, it becomes a more complex 
form of Extensively drug-resistant tuberculosis (XDR-TB), also known as 
super tuberculosis. With this relationship, it is becoming more important than 
ever to develop new drugs for resistant tuberculosis.
1.4 Toxin– antitoxin System
We are mainly studying Toxin-antitoxin System as a target for new drug 
development. The TA system is found in almost all bacteria and some 
fungi. [Yoshihiro Yamaguchi, Jung-Ho Park, and Masayori Inouye., 2011] 
Normally, cognate antitoxin against toxin and toxin are complexed and toxin 
is not activated. In a stress condition such as nutrition starvation and 
antibiotics, the less stable antitoxin is rapidly degraded and a single, free 
active toxin targets the essential processing steps of cells such as DNA 
replication and cell wall synthesis to prevent the growth of damaged cells, it 
leads to cell death and lowers susceptibility to antibiotics. [Kenn Gerdes and 
Etienne Maisonneuve., 2012]
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TA systems are divided into six groups according to the mechanism of TA 
gene regulation and the characteristics of antitoxin. Among them, Type 2 is 
the antitoxin protein which directly binds to toxin protein and inhibits the 
toxicity of toxin. In M. tuberculosis, the most abundant family is the type 2 
TA system in which 67 out of 79 TA belongs.
And M. tuberculosis has the most diverse Toxin-Antitoxin systems among 
bacteria. The greatest feature of M. tuberculosis as a germ is its ability to 
survive for long periods of time in a host-resistant, non-multiplying state, 
and then wake up again later to cause disease. One of the notable areas of 
attention to demonstrate this capability is that it has a vast number of 
toxin-antitoxin systems, presuming that the activation of the TA system will 
form the pathogenesis and the possibility of TA with other bacteria is being 
studied. [Ambre Sala, Patricia Bordes and Pierre Genevaux., 2014]
1.5 Characteristics of Rv0660c
Rv0660c is a Type 2 toxin-antitoxin system of Mycobacterium tuberculosis 
with Rv0659c. Rv0659c is a toxin known as MazF2 and Rv0660c is an 
antitoxin known as MazE2. Rv0660c is 81 amino acids with a molecular 
weight of 9kDa (9169) and theoretical PI is 4.4.
At first, full-length experiments failed to form crystals because they were 
well resolved during the purification process. Therefore, we excluded the 
flexible c-terminal part, which was well disassembled, and tried to divide 
the N-terminal part into several parts by looking at the expected secondary- 
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structure through J-pred. The length of the sample that succeeded in the 
crystallization was 1-44.
1.6 Purpose of the study
The purpose of this study is to identify the tertiary structure of the N1-44 
construct of Rv0660c through x-ray crystallography and to obtain 
information on DNA binding through NMR and EMSA experiments. 
To accomplish this goal, the N-terminal parts of Rv0660c were selected 
and cloned. Cloned samples were transformed into competent cells for 
expression and then overexpressed using E. coli. Over-expressed proteins 
were able to undergo solubility testing and purification. The purified sample 
was crystallized through crystallization and the tertiary structure was obtained 
with a high resolution of 1.69 Å. 
Various NMR and EMSA experiments were performed to obtain 
information on DNA binding. Particularly, at this time, we could confirm 
which parts of the tertiary structure bind DNA in comparison with the 
structure obtained through crystal.
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Ⅱ. Materials and Methods
2.1 Materials
2.1.1 Reagents
The genomic DNA of Mycobacterium tuberculosis H37Rv was purchased 
from BIONEER. Expression host E. coli codon plus(DE3) and pET-28a (+) 
expression vector were bought from Novagen Inc. (Darmstadt, Germany). 
Sequencing service was from Cosmogenetech Service. PCR premix kits were 
purchased from INTRON Biotechnology Inc. PCR primer bought from 
BIONEER. T4 DNA ligase, T4 DNA ligase buffer were purchased from 
TaKaRa Inc. BSA, Restriction endonucleases, and buffer4 were purchased 
from New England Biolabs(NEB). Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) and LB media were purchased from Calbiochem (Nottingham, UK). 
Kanamycin was bought from Biosesang. Vitamins solution and other reagents 
to make buffer solutions and media for M9 were bought from SIGMA (St. 
Louis, USA). 15NH4Cl and 13C-glucose for isotope labeling were bought 
from Cambridge Isotope (Andover,MA,USA). Ni2+-affinity column resin 
which is HisTrap HP column was from GE Healthcare Life Sciences (Little 
Chalfont, United Kingdom). All reagents and chemicals were purchased from 




PCR reaction was carried out by Perkin-Elmer PCR system 9600 
(Perkin-Elmer, USA). The concentration of protein was measured using 
NanoDrop ND-1000 from Coleman Technologies Inc. (Wilmington, DE, 
USA). Cell lysis was performed by the sonic oscillator, sonifier450 designed 
by Branson Ultrasonic Corporation (Connecticut, USA). J2-MC and the 
fraction collector were bought from Bio-Rad Laboratories Inc. (California, 
USA). Centricon, Centriprep were bought from Millipore Corporation 
(Massachusetts, USA). Ni2+-affinity Chromatography was conducted by 
HisTrap HP column in fast protein liquid chromatography (FPLC) (AKTA 
prime, GE Healthcare, USA). Size Exclusion Chromatography was conducted 
by superdex 75 16/200 column fast protein liquid chromatography (FPLC) 
(AKTA, GE Health care, USA). NMR tubes were prepared from Shigemi 
Inc. (Tokyo, Japan). All NMR spectra were recorded on JEOL 600MHz 
NMR spectrometer (JEOL Ltd., Tokyo, Japan). All NMR measurements were 
analyzed by Bruker NMR systems 600MHz (California, USA). All NMR 
data were processed by NMRpipe, NMRDraw and NMRView from Silicon 
Graphic Inc. (California, USA).
2.2 Methods
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2.2.1 Cloning of target protein
The N1-44 of Rv0660c gene was amplified by PCR from M. tuberculosis 
H37Rv genomic DNA. PCR was carried out under general procedure. The 
sense and antisense oligonucleotide primers contained the restriction enzyme 
sites, NdeI and XhoI, respectively. Consecutive six histidine residues were 
tagged to the carboxyl terminus of protein in order to increase the efficiency 
of purification. The amplified target protein was cloned into the expression 
vector pET-28a(+) (Novagen) that was digested by both NdeI and XhoI 
(Figure 1). After ligation process between truncated PCR inserts and 
truncated vectors, the recombinant plasmids were transformed to competent 
cell, E. coli DH5α. After sequence analysis of the recombinant plasmids, 
they were transformed to E. coli cells of BL21(DE3), Codon plus(DE3), 
C41 and Rosetta2(DE3) for protein over expression test with IPTG.
Figure 1. pET-28a (+) cloning vector.
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2.2.2 Protein Over-expression and purification
Each of the transformed BL21(DE3), Codon plus(DE3), C41 and 
Rosetta2(DE3) cells was grown in 5 ml of LB media with 5 μl of 
kanamycin (30μg/ml) at 37°C and a shaking speed of 180 RPM overnight. 
Next day, they were inoculated into 200 ml of the fresh autoclaved LB 
media each containing 200μl of kanamycin and incubated at 37°C and a 
shaking speed of 180 RPM until the value of Optical Density (O.D.) at 600 
nm was approximately 0.5. 200μl from each of the cultured cells was 
obtained to micro centrifuge tubes. They were centrifuged for 5 minutes at 
13,000 RPM to save pellet only for later analysis. 200μl of 
isopropyl-β-D-1-thiogalactopyranoside (IPTG, 0.5μg/ml of final concentration) 
was added to each of the cultured cells to induce expression. After 4 hours, 
we took 200μl from each of the induced cells and removed supernatants 
after centrifugation. The pellet fractions for both pre-samples and post 
induced samples were suspended in 50μl of distilled water and boiled for 10 
minutes. 
We ran SDS-PAGE electrophoresis to observe the presence of induced 
band. Overexpressed cells were harvested by a centrifugation (Beckham 
J2-MC) at 4°C and 10,000 RPM for 10 minutes. The cell pellet was 
suspended in 30 ml of the lysis buffer (20mM Tris-HCl (pH 7.8) and 
500mM NaCl) at 4°C. The suspended cells were disrupted by an ultrasonic 
homogenizer on ice bath for total 10 minutes (pulse on 1 second, pulse off 
5 seconds) at 30% amplitude. The lysate was clarified by centrifugation at 
18,000 RPM for 1 hour at 4°C. The pellet extraction and supernatant were 
tested on SDS-PAGE to confirm protein’s solubility.
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For NMR spectroscopy, 15N-labeled and 15N,13C-labeled protein sample was 
prepared following the procedure above. The seed strain was inoculated in 
5ml of LB media containing kanamycin(30μg/ml) at 37°C with shaking at- 
180 RPM overnight. They were inoculated in 10ml of M9 media without 
isotope labeled carbon and nitrogen sources for 9 hours at 37°C. The cells 
were scared up in 1L of M9 minimal media supplemented with 1g 
13C-glucose and 1g 15N-NH4Cl. After sonication, the supernatant was filtered 
by 0.45μm syringe filter and loaded into a Ni2+ affinity column, which had 
been previously equilibrated with the basic buffer (20mM Tris-HCl (pH7.8) 
and 500mM NaCl). Then, the column was washed with the same buffer at 
gravity flow. The target protein was eluted by a stepwise concentration 
gradient of imidazole from 50 to 500mM.
The elution fractions were checked visually by SDS-PAGE electrophoresis 
and concentrated by ultrafiltration using an Amicon Ultra-15 centrifugal filter 
unit (Millipore,USA) up to 2ml. Concentrated samples were cleaved with 
Thrombin overnight at 4°C to remove His-tag and then loaded onto IMAC 
to purify only Rv0660c without His-tag. The solution was then concentrated 
until the concentration of target protein becomes approximately 0.2mM. All 
the purified fractions were analyzed by SDS-PAGE electrophoresis and 
concentrated by ultrafiltration using an Amicon Ultra-15 centrifugal filter unit 
(Millipore, USA).
2.2.3 Crystallization
Crystallization conditions were searched by the sitting drop vapor-
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diffusion method at 20℃ using screening kits from Hampton Research Inc.
(Crystal Screen I, II, Index I, II) and from Emerald Biosystems Inc. 
(Wizard I, II, III, and IV). The crystallization drops were made by mixing 
the protein solution and the reservoir solution in one-on-one ratio. The 
well-made crystals appeared in- 2-3 days in optimized reservoir solution 
consisting of 0.1 M Tris pH 8.5, 0.3 M Magnesium formate dihydrate. By 
optimizing this buffer condition, we could get a better crystal. The crystal 
was vitrified using the cryoprotectant solution consisting of the reservoir 
solution supplemented with 20% (v/v) glycerol. Crystals were soaked in the 
cryoprotectant solution for a few seconds before being frozen in liquid 
nitrogen.
2.2.4. X-ray data collection and structure 
determination
X-ray diffraction data was collected using synchrotron radiation on ADSC
Q315r detector at beamline PAL-5C (SBII) (Pohang, South Korea) at 
λ=0.97944. Raw data was processed and scaled using HKL2000 program 
package. [Otwinowski and Minor., 2002] The structure was determined by 
molecular replacement using the phase program in CCP4 suite of programs 
and Phenix. [Adams et al., 2010] Coot was used for manual model. 
[Emsley and Cowtan., 2004]
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2.3 Structural and Functional studies by NMR 
spectroscopy
2.3.1 NMR data collection 
NMR spectra were collected by JEOL 600 MHz NMR spectrometer 
equipped with a triple resonance probe and xyz-pulsed field gradient unit. 
2D-15N HSQC at 298K(25°C) and 303K (30°C) were recorded using 1mM 
concentration of 15N-labeled Rv0660c protein in 20mM Tris-HCl(pH 7.8), 
500mM NaCl and 10 % D2O. 3D NMR spectra for backbone assignments 
(HNCA, HN(CO)CA, HNCACB, CBCA(CO)NH, HN(CA)CO and HNCO) 
were measured using 1mM of 15N, 13C-labeled protein at 298K(25°C) in 
same buffer condition above. All NMR datasets were processed in NMRPipe 
[Delaglio et al., 1995] and analyzed in NMR View Program. [Johnson BA 
and Belvins RA., 1994]
2.3.2 Backbone assignment
2D 1H-15N HSQC was first step for structural studies. It was measured at 
298K(25°C) and 303K (30°C) in order to find the proper temperature for 
3D NMR experiments. 1H chemical shift values were referenced to DSS and 
15N chemical shift values were referenced indirectly by multiplying the 1H- 
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carrier frequency. Each peak in 2D-HSQC spectrum should correspond to an 
amino acid residue in the sequence of N1-44 of Rv0660c. HNCA, 
HN(CO)CA, HNCO, HN(CA)CO, HNCACB and CBCA(CO)NH spectra were 
recorded to assign chemical shift values for 1HN, 15N, 13CO, 13Cα and 13Cβ 
of a protein backbone. The phase was correctly adjusted in NMRPipe and 
the processing script with optimized parameter was executed. [Delaglioet al., 
1995] The sequence-specific resonance assignments were performed using 
standard procedures in NMR View. [Johnson BA and Belvins RA., 1994]
2.3.3 Secondary structure prediction based on 
TALOS
The secondary structure of Rv0660c was predicted by TALOS sever based 
on assigned chemical shift values of Rv0660c. TALOS program is a 
protein`s secondary structure prediction program. We input assigned chemical 
shift values of the protein backbone (1HN, 15N, 13CO, 13Cα and 13Cβ) and 
N1-44 of Rv0660c protein sequence information into TALOS web server. It 
calculated phi and psi backbone torsion angles and provided secondary 
structure information with the Ramachandran plot where the residue is 
probable to reside in.
2.3.4 DNA synthesis and preparation
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NMR spectroscopy also can be used to exam structural perturbations upon 
complex formation. It provides information about chemical shift changes of 
amino acid residues involved in the interaction protein and DNA. We 
synthesized a 20-mer double stranded oligonucleotide sequence from 
BIONEER to study function of DNA binding. The sequence is shown in 
Figure 2.  
Figure 2. The DNA oligonucleotide sequence for NMR titration experiment.
First, 2D 1H-15N HSQC for N1-44 of Rv0660c protein was measured at 
298K(25°C) as the reference. The concentration of N1-44 of Rv0660c 
protein was 1mM in 20mM Tris-HCl(pH 7.8), 500mM NaCl and 10 % 
D2O. And then, 2D 1H-15N HSQC spectra were recorded with a gradient of 
protein:DNA=1:0 to 1:0.2, 1:0.4, 1:0.6. All these NMR spectra were also 
processed and analyzed by NMRPipe and NMRView.
2.4 Electrophoretic Mobility Shift Assay (EMSA)
The 5′-biotinylated DNA oligonucleotides used for EMSA contained- 
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complementary single strand DNA having sequence 5′- 
GGCCGGCGGAGGACTGGGCC -3′ and 5′- CCGGCCGCCTCCTGACCCGG 
-3′. Binding reaction mixtures (20μl) containing 10μM N1-44 of Rv0660c 
protein and increasing amounts of DNA(10, 50, 100, 200μM) in 20mM 
Tris-HCl(pH7.8), 500mM NaCl were incubated at 25 °C for 10 min. After 
reaction at 25 °C for 10 min, the mixtures were then loaded on a 10 % 
polyacrylamide gel in 0.5×TBE buffer at 100V for non-denaturing 
electrophoresis and transferred to a nylon membrane for detection using the 
Light-shift EMSA kit (Thermo Fisher Scientific, Inc.) and analyzed using 




3.1.1 Cloning, overexpression and purification
N1-44 of Rv0660c was transcribed under control of the T7 promoter and 
lac operator in pET-28a vector. The protein was highly expressed in E. coli 
codon plus(DE3) at 37°C incubation and fully soluble. The result of- 
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expression is given in Figure 3. Ni2+ ions which immobilize by forming 
covalent bonds with his-tag recombinant proteins are commonly used. We 
used the Ni2+ affinity column for the first purification process. The purified 
proteins were eluted in the presence of 100–350mM imidazole. Figure4 
shows SDS-PAGE of the first purification result. Subsequently, purified 
Rv0660c1-44 was cut overnight with Thrombin at 4°C to remove His-tag. 
Figure5 shows SDS-PAGE of Rv0660c1-44 with His-tag removed. The 
complete Rv0660c1-44 with His-tag removed can be obtained by loading 
again on the Ni2+ affinity column. After purification, The final 
Concentration of Rv0660c1-44 was about 1mM.
Figure 3. SDS-PAGE result of over expression test of Rv0660c1-44.
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Figure 4. SDA PAGE result of purification of Rv0660c1-44 by using Ni2+ affinity- 
column.




The crystals of Rv0660c1-44 made by sitting-drop vapor diffusion are shown 
in figure 6. crystals which were formed in 0.1 M Tris pH 8.5, 0.3 M 
Magnesium formate dihydrate could diffract X-ray well. Crystals of  
Rv0660c1-44 look like columnar shape. When we optimize the buffer 
conditions for this crystal hit, we can get a crystal of a much bigger and 
better shape and the shape look like octahedron. The big and sharp crystal 
of N1-44 of Rv0660c is shown in figure 7.
Figure 6. The crystals of Rv0660c1-44.
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Figure 7. The optimized crystals of Rv0660c1-44.
3.2 Crystal structure of Rv0660c1-44
Figure 8. shows the crystal structure of the Rv0660c1-44. Two monomers each 
consisting of one β-sheet and two α-helix form antiparallel homodimers and 
it seems that it has a ribbon-Helix-Helix motif as a DNA binding domain.
-19-
Figure 8. The crystal structure of Rv0660c1-44 dimer.
        
3.3 NMR studies of 15N or 15N-13C labeled 
Rv0660c1-44
3.2.1 2D 1H-15N HSQC
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Figure 9 shows 1H-15N HSQC spectrum of Rv0660c1-44 at the optimized
buffer condition. Since temperature also affects rate of folding in the tertiary 
structure of protein, we observed 2D 1H-15N HSQC spectra at 298K (25°C) 
and 303K (30°C). There are more cross peaks with high intensity at 298K 
(25°C) and the peaks were spread out very well. It means Rv0660c1-44 
protein is folded in the most stable form at 298K(25°C). The concentration 
of protein is 1 mM in 20mM Tris-HCl (pH 7.8) and 500mM NaCl.
3.2.2 Sequential backbone assignment
For the backbone assignments of Rv0660c1-44, six NMR spectra of 15N-13C 
labeled Rv0660c1-44 were carried out; HNCA, HN(CO)CA, HNCO, 
HN(CA)CO, HNCACB and HN(CO)CACB.
HN(CO)CA, HN(CO)CACB and HNCO correlate inter-residue and HNCA, 
HNCACB and HN(CA)CO correlate both inter and intra-residue. HN(CO)CA 
that gives 1HN(i), 15N(i) and 13Cα(i-1) chemical shifts and HNCA that gives 
chemical shifts of 1HN(i), 15N(i), 13Cα(i-1) and 13Cα(i), were used to assign C
α resonance signals. HNCACB that provides chemical shift data of 1HN(i), 
15N(i), 13Cα(i), 13Cβ(i), 13Cα(i-1) and 13Cβ(i-1) was used, in tandem with 
HN(CO)CACB that correlates 1HN(i), 15N(i), 13Cα(i-1) and 13Cβ(i-1), to 
identify Cβ resonance signals. HN(CA)CO that gives 1HN(i), 15N(i), 13C(i) 
and 13C(i-1) chemical shifts and HNCO that provides chemical shift data of 
1HN(i), 15N(i) and 13CO(i-1) were combined to determine 13C chemical shifts.
Approximately 95% of backbone assignment was completed. Figure 9 
shows a 2D 1H-15N HSQC spectrum with assigned peaks of Rv0660c1-44 at 
the optimal buffer condition.
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Figure 9. 2D 1H-15N HSQC spectrum of Rv0660c1-44. Numbers indicates sequence- 
numbers and capital letters are single-letter codes for amino acids.
3.3.3 Predicted secondary structure of Rv0660c1-44
Using the acquired chemical shift value and other information from NMR 
spectrum, we requested TALOS server to predict secondary structure. 
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Basically, the meaning of ‘-1’ is the α-helix tendency and the meaning of 
‘1’means the β-strand tendency of the atom of the residue. Meaning of ‘0’ 
is the chemical shift within the reference value range. Figure 10 shows 
Secondary structure prediction based on TALOS. And, as shown in the 
figure 10, it can be seen that the structure of one β-sheet and two α -helix 
is the same as the tertiary structure identified by X-ray crystallography.




In order to identify the property of DNA binding and determine the binding 
site of Rv0660c1-44, We performed a NMR protein-DNA titration experiment. 
The DNA sequence was a double stranded and a palindrome sequence 
located in promoter region of Rv0660c1-44. Overlap of HSQC cross peak 
patterns of free and DNA-bound protein showed that several peaks were 
shifted (Figure 11). And, as you know, figure 2 shows The DNA sequence 
that we deigned.
By plotting HSQC by concentration of protein and DNA, you can see 
where the chemical shifts have changed so you can see where the 
interaction occurs when binding to DNA. It can be seen that the position of 
the residues of Peak's movement is shown in red in the crystal model 
(Figure 12). 
The following figure13 is a graph of Intensity loss. When HSQC is 
photographed through DNA titration, it can be understood that the DNA will 
directly bind to the portion where the intensity loss is severe. The residues 
that are expected to bind directly are shown in purple on the Crystal model 
(figure 14).
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Figure 11. The shifted peaks of NMR titration experiments.
Figure 12. The crystal structure of Rv0660c1-44 within formation on DNA binding.
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Figure 13. The intensity loss graph of Rv0660c1-44 due to DNA binding.
Figure 14. The crystal structure of Rv0660c1-44 within formation on direct DAN- 
binding.
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3.4.2 Comprehensive result of Protein-DNA binding
Thus, Rv0660c, antitoxin, can be seen that DNA will bind the side chains 
of the residues of the purple moiety seen in the Ribbon model of the 
following structure (figure 15). In the typical RHH motif of DNA-binding 
proteins, residues such as Lysine and Arginine, which have a particularly 
positive charge, are known to bind directly to the DNA backbone (figure 
16). In the electrostatic charge model of the following surface, it can be 
seen that the part to be bound has a positive charge and that Rv0660c 
interacts with DNA as in the DNA binding model of RHH motif (figure 
17).
Figure 15. The ribbon model of Rv0660c1-44.
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Figure 16. The electrostatic charge model of Rv0660c1-44.
Figure 17. The DNA binding model on RHH motif.
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3.4.3 Electrophoretic Mobility Shift Assay (EMSA)
It is an experiment to check DNA binding activity of protein in vitro. DNA 
was used as a probe and the protein concentration was adjusted to a 
gradient. And, as you know, figure2 shows The DNA sequence that we 
deigned. After the reaction was carried out for a certain period of time, the 
reaction samples were loaded on agarose gel and electrophoresis revealed 
that Rv0660c binds to the palindromic sequence of the promoter DNA of 
the MazEF gene as you can see that the bend shifts up (figure 18). This 
shows that Rv0660c functions as a transcriptional factor.




The structure of Rv0660c1-44 was obtained by x-ray crystallography, and 
NMR and EMSA experiments were performed to obtain information on 
DNA binding. The NMR experiments showed that the secondary structure 
could be predicted, which is actually the same as the crystal structure. Also, 
through DNA titration, the backbones with greatly changed chemical shifts 
could be identified by the site of DNA interaction. And we could confirm 
the DNA binding activity of Rv0660c in vitro through EMSA.
 Therefore, DNA binding information of antitoxin can be used as a part of 
the antibacterial strategy when TA gene promoter is combined with 
antitoxin-like compound to act as TA gene repressor and activate toxin to 
cause cell death. 
 Once the TA system has been studied as an antibacterial strategy through 
artificial activation. It is the ability to disrupt the complex through a 
compound that binds to a toxin or antitoxin, rather than a stress condition, 
and then to exert its toxin function to cause cell death. Among them, 
MazEF is the most popular TA. It is the most efficient way to combine 
with antitoxin to free toxin. This is because the way to disrupt the complex 
in combination with toxin depends on which part of the toxin is bound, 
which may affect the activity of the toxin. [Julia J. Williams and Paul J. 
Hergenrother., 2012] 
Therefore, it is important to note the structure of antitoxin and DNA 
biding information when approaching new drug development by disruption of 
TA complexes and by inhibiting complex formation. 
-30-
Ⅴ. References
Issar Smith, et al. (2003). Mycobacterium tuberculosis pathogenesis and 
molecular determinants of virulence. Clin Microbiol Rev. 16(3): 463-496.
World Health Organization. (2015). Fact sheets. 
http://www.who.int/mediacentre/factsheets/fs104/en/. (Accessed 15 May 2015)
Yoshihiro Yamaguchi, Jung-Ho Park, and Masayori Inouye. (2011). 
Toxin-Antitoxin Systems in Bacteria and Archaea. Annual Review of 
Genetics. 45: 61-79.
Kenn Gerdes and Etienne Maisonneuve. (2012). Bacterial Persistence and 
Toxin-Antitoxin Loci. Annual Review of Microbiology. 66: 103-23.
Ambre Sala, Patricia Bordes and Pierre Genevaux. (2014). Multiple 
Toxin-Antitoxin Systems in Mycobacterium tuberculosis. Toxins. 6, 
1002-1020. 
Minor, W., Cymborowski, M., Otwinowski, Z. (2002). Automatic system for 
crystallographic data collection and analysis. Acta. Phys. Pol. A 101:613-619.
-31-
P. D. Adams, P. V. Afonine, G. Bunkóczi, V. B. Chen, I. W. Davis, N. 
Echols, et al. (2010). PHENIX: a comprehensive Python-based system for 
macromolecular structure solution. Acta Cryst. D66, 213-221.
P. Emsley and K. Cowtan. (2004). Coot: model-building tools for molecular 
graphics. Acta Cryst. D60, 2126-2132.
Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. (1995). 
NMRPipe: a multidimensional spectral processing system based on UNIX 
pipes. J Biomol NMR. 6(3): 277-93.
Johnson BA, Blevins RA. (1994). NMR View: A computer program for the 
visualization and analysis of NMR data. J Biomol NMR. 4(5): 603-14.
Julia J. Williams and Paul J. Hergenrother. (2012). Artificial activation of 
toxin-antitoxin systems as an antibacterial strategy. Trends in Microbiology. 
Vol. 20, No. 6.
Yurong Wen, Ester Behiels and Bart Devreese. (2014). Toxin-Antitoxin 
systems: their role in persistence, biofilm formation, and pathogenicity. 
Pathogens and Disease. 70, 240-249.
-32-
Laurence Van Melderen. (2010). Toxin-antitoxin systems: why so many, 
what for?. Current Opinion in Microbiology. 13: 781-785.
Nathalie Goeders and Laurence Van Melderen. (2014). Toxin-Antitoxin 
Systems as Multilevel Interaction Systems. toxins. 6, 304-324.
Schreiter et al. (2007). Protein-DNA-interaction-Regulation of gene 
expression. Strukturbiologie.
Remy Loris, Irina Marianovsky, Jurij Lah, Toon Laeremans, Hanna 
Engelberg-Kulka, Gad Glaser., et al. (2003). Crystal Structure of the 
Intrinsically Flexible Addiction Antidote MazE. THE JOURNAL OF 
BIOLOGICAL CHEMISTRY. Vol. 278, No.30, 28252-28257. 
Christian Dienemann, Andreas Bøggild, Kristoffer S. Winter, Kenn gerdes 
and Ditilev E. Brodersen. (2011). Crystal Structure of the VapBC 
Toxin-Antitoxin Complex from Shigella flexneri Reveals a Hetero-Octameric 
DNA-Binding Assembly. Journal of Molecular Biology. 414, 713-722.
Robert Schleif. (1988). DNA Binding by Proteins. Science. 241, 4870.
-33-
Valentina Zorzini, Lieven Buts, Evelyne Schrank, Yann G.J. Sterckx, Michal 
Respondek, Hanna Engelberg-Kulka., et al. (2015). Eschericia coli antitoxin 
MazE as transcription factor: insights into MazE-DNA binding. Nucleic 
Acids Research.
Martin Overgaard, Jonas Borch and Kenn Gerdes. (2009). RelB and RelE of 
Escherichia coli Form a Tight Complex That Represses Transcription via the 
Ribbon-Helix-Helix Motif in RelB. J. Mol. Biol. 394, 183-196. 
Andreas Bøggild, Nicholas Sofos, Kasper R. Andersen, Ane Feddersen, 
Ashley D. Easter, Lori A. Passmore, et al. (2012). The Crystal Structure of 
the Intact E. coli RelBE Toxin-Antitoxin Complex Provides the Structural 
Basis for Conditional Cooperativity. Structure. 20, 1641-1648.
Gerhard Mittenhuber. (1999). Occurence of MazEF-like Antitoxin/Toxin 
Systems in Bacteria. J. Mol. Microbiol. Biotechnol. 1(2): 295-302.
-34-
국문초록
결핵균(Mycobacterium tuberculosis)은 1882년 Robert Koch에 
의해서 처음 발견되었으며, 인체 감염성 균주로서 호흡기를 통해 폐에 
질병을 일으킨다. Mycobacterium은 일반적인 세균과는 달리 세포 
표면에 두터운 협막을 갖고 있어 그람 염색이 되지 않으나 
Ziehl–Neelsen으로 염색시 산, 알코올, 끓이는 것 등에 의해서도 
탈색되기 어려우며, 이 성질을 항산성(acid-fast)이라 한다. 그람 염색 
여부로는 음성이지만, 이들은 외부 세포막이 없어서 항산성 그람 양성 
세균으로 분류된다. 결핵균에 감염된 환자의 치료는 주로 약에 의해 
이루어지며 쓰이는 약물로는 이소니아지드, 리팜핀, 피라진아미드 등이 
쓰이며 스트렙토마이신 등이 쓰이기도 한다.
결핵균에는 세균 중 가장 많은 Toxin-Antitoxin system 쌍이 
존재한다. Toxin-Antitoxin system은 antitoxin 성질에 따라 여섯 
가지 종류로 분류되며 본 연구의 타겟 단백질인 Rv0660c는 Type2 
Toxin-Antitoxin system의 하나인 MazEF system의 antitoxin인 
MazE다.
Toxin-Antitoxin system은 외부 자극에 의해 활성화된 toxin이 균의 
성장을 저해하거나 사멸로 이끄는 역할을 한다. Antitoxin은 평상시 
toxin과 결합하여 toxin의 활동을 저해하지만 극한상황이 되었을 때 
분해된다. 이로 인해 해리된 toxin이 성장 저해, 사멸 등을 유도한다. 
이는 또한 잠복기를 유도하여 항생제에 감수성을 떨어뜨리게 만든다.
본 연구는 이 Rv0660c 단백질의 삼차구조를 규명하기 위해 
Rv0660c의 N1-44 construct를 과 발현시켰다. 
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Immobilized Metal Affinity Chromatography(IMAC)를 이용하여 
His-tag을 붙인 Rv0660c 단백질을 정제하였고, Thrombin cutting을 
거쳐 His-tag을 제거하여 단백질의 순도를 더욱 높여 만들어낸 
crystal로 1.69Å의 높은 resolution으로 구조를 구할 수 있었다.
NMR, EMSA를 통하여 Rv0660c의 DNA binding실험을 진행하였다. 
Rv0660c를 13C와 15N의 동위원소로 label하여 heteronuclear 
multidimensional NMR spectrum을 측정하여, HNCO, HNCA, 
HNCACO, HNCOCA, HNCOCACB, HNCACB spectrum을 통해 
backbone assignment를 하였다. TALOS 프로그램을 이용하여 
2차구조를 예상했으며 DNA titration을 통해 DNA와 상호작용하는 
부분을 규명하였다. Electrophoretic Mobility Shift Assay(EMSA)를 
통해 in vitro에서 Rv0660c의 DNA 결합 여부도 확인하였다.
주요어: SBDD(Structure Based Drug Design), Toxin-Antitoxin system, 
Antitoxin, x-ray crystallography, NMR(Nuclear Magnetic Resonance), 
EMSA(Electrophoretic Mobility Shift Assay)
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